Figure 3
ADCC activity of BA9 and BT942. (a,b) ADCC was evaluated for BA9 and BT942 by a reporter bioassay. The target cells were SU-DHL-1 (a) or 293T-CD25 (b), the effector cells were Jurkat cells from Promega. BA9 can induce higher ADCC activity to both cell lines than BT942. Experiments were performed in duplicate. Data were presented as mean ± SEM. (c,d) ADCC was evaluated for BA9, BT942 and daclizumab by PBMC-mediated cytotoxicity. The target cells were SU-DHL-1 (c) or HEK293T-CD25 cells (d), the effector cells were PBMC. BA9 has higher ADCC activity than BT942. Experiments were performed in duplicate. Data were presented as mean ± SEM. (e,f) ADCC against activated CD8+T cells was evaluated for BA9 and BT942. The target cells were activated CD8+T cells. ADCC was evaluated by a reporter bioassay and the effector cells were Jurkat cells (e). ADCC was evaluated by PBMC-mediated cytotoxicity and the effector cells were PBMC (f). Experiments were performed in duplicate. Data were presented as mean ± SEM.
